{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:50:30Z","timestamp":1792108230560,"version":"4.4.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01193-0","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:21:58Z","timestamp":1792106518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies"],"prefix":"10.1038","author":[{"given":"Siamak","family":"Daneshmand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5510","authenticated-orcid":false,"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-2723","authenticated-orcid":false,"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6929-6124","authenticated-orcid":false,"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1747-9615","authenticated-orcid":false,"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn S.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1193_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75\u201394 https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010 (2022).","journal-title":"Eur. Urol."},{"key":"1193_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J. Urol. 196, 1021\u20131029 https:\/\/doi.org\/10.1016\/j.juro.2016.06.049 (2016).","journal-title":"J. Urol."},{"key":"1193_CR3","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 1 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (National Comprehensive Cancer Network, 2025)."},{"key":"1193_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.32948\/auo.2024.08.25","volume":"7","author":"A Gupta","year":"2024","unstructured":"Gupta, A. et al. Treatment strategies for BCG unresponsive non-muscle-invasive bladder cancer. Ann. Urol. Oncol. 7, 97\u2013109 https:\/\/doi.org\/10.32948\/auo.2024.08.25 (2024).","journal-title":"Ann. Urol. Oncol."},{"key":"1193_CR5","unstructured":"BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry https:\/\/www.fda.gov\/media\/101468\/download (US Department of Health and Human Services, 2018)."},{"key":"1193_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","volume":"27","author":"SP Lerner","year":"2009","unstructured":"Lerner, S. P., Tangen, C. M., Sucharew, H., Wood, D. & Crawford, E. D. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol. Oncol. 27, 155\u2013159 https:\/\/doi.org\/10.1016\/j.urolonc.2007.11.033 (2009).","journal-title":"Urol. Oncol."},{"key":"1193_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/ju.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein, J. M. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment. J. Urol. 211, 533\u2013538 https:\/\/doi.org\/10.1097\/ju.0000000000003846 (2024).","journal-title":"J. Urol."},{"key":"1193_CR8","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.21037\/tau.2020.03.23","volume":"9","author":"K Aminoltejari","year":"2020","unstructured":"Aminoltejari, K. & Black, P. C. Radical cystectomy: a review of techniques, developments and controversies. Transl. Androl. Urol. 9, 3073\u20133081 https:\/\/doi.org\/10.21037\/tau.2020.03.23 (2020).","journal-title":"Transl. Androl. Urol."},{"key":"1193_CR9","unstructured":"Gontero, P. et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2024.pdf (2024)."},{"key":"1193_CR10","unstructured":"ADSTILADRIN (Nadofaragene firadenovec-vncg) Suspension, for Intravesical Use (Ferring Pharmaceuticals, 2022)."},{"key":"1193_CR11","unstructured":"KEYTRUDA (Pembrolizumab) Injection, for Intravenous Use https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf (Merck & Co., 2024)."},{"key":"1193_CR12","unstructured":"ANKTIVA (Nogapendekin alfa inbakicept-pmln) Solution, for Intravesical Use https:\/\/anktiva.com\/wp-content\/uploads\/ANKTIVA-Annotated-Approved-Label-Clean.pdf (Altor BioScience, 2024)."},{"key":"1193_CR13","unstructured":"VALSTAR (Valrubicin) Solution, for Intravesical Use (Endo Pharmaceuticals Solutions Inc., 2016)."},{"key":"1193_CR14","unstructured":"Inlexzo (Gemcitabine Intravesical System) https:\/\/www.janssenlabels.com\/package-insert\/product-monograpg\/prescribing-information\/INLEXZO-pi.pdf (Janssen Biotech Inc, 2025)."},{"key":"1193_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","volume":"53","author":"WS Tan","year":"2023","unstructured":"Tan, W. S. et al. Bladder-sparing treatment in patients with bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: an analysis of long-term survival outcomes. Eur. Urol. Open Sci. 53, 16\u201322 https:\/\/doi.org\/10.1016\/j.euros.2023.04.013 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"1193_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin, H., Wang, L. & Bernards, R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat. Rev. Drug Discov. 22, 213\u2013234 https:\/\/doi.org\/10.1038\/s41573-022-00615-z (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1193_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15\u201325 https:\/\/doi.org\/10.1038\/cdd.2013.67 (2014).","journal-title":"Cell Death Differ."},{"key":"1193_CR18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas, A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915\u2013919\u00a0https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0563 (2015).","journal-title":"Cancer Discov."},{"key":"1193_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537808","volume":"16","author":"P Huang","year":"2025","unstructured":"Huang, P. et al. Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion. Front. Immunol. 16, 1537808 https:\/\/doi.org\/10.3389\/fimmu.2025.1537808 (2025).","journal-title":"Front. Immunol."},{"key":"1193_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1670574","volume":"15","author":"J Xiang","year":"2025","unstructured":"Xiang, J., Luo, Y., Zhang, B., Ke, K. & Li, H. Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy. Front. Oncol. 15, 1670574 https:\/\/doi.org\/10.3389\/fonc.2025.1670574 (2025).","journal-title":"Front. Oncol."},{"key":"1193_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1719978","volume":"13","author":"A Di Spirito","year":"2025","unstructured":"Di Spirito, A. et al. Evolving frontiers in bladder cancer immunotherapy: integrating BCG, immune checkpoints, viral vectors, nanotechnology, and CAR-based therapies. Front. Cell Dev. Biol. 13, 1719978 https:\/\/doi.org\/10.3389\/fcell.2025.1719978 (2025).","journal-title":"Front. Cell Dev. Biol."},{"key":"1193_CR22","unstructured":"Gemzar for injection: 200 mg or 1 gram lyophilized powder in single-dose vials for reconstitution. Lilly USA https:\/\/uspl.lilly.com\/gemzar\/gemzar.html#pi (2019)."},{"key":"1193_CR23","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini, E., Nobili, S., Caciagli, B., Landini, I. & Mazzei, T. Cellular pharmacology of gemcitabine. Ann. Oncol. 17, v7\u2013v12 https:\/\/doi.org\/10.1093\/annonc\/mdj941 (2006).","journal-title":"Ann. Oncol."},{"key":"1193_CR24","unstructured":"TAXOTERE (Docetaxel) Injection, for Intravenous Use https:\/\/products.sanofi.us\/taxotere\/taxotere.html (Sanofi-Aventis, 2021)."},{"key":"1193_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00003088-200645030-00002","volume":"45","author":"SD Baker","year":"2006","unstructured":"Baker, S. D., Sparreboom, A. & Verweij, J. Clinical pharmacokinetics of docetaxel : recent developments. Clin. Pharmacokinet. 45, 235\u2013252 https:\/\/doi.org\/10.2165\/00003088-200645030-00002 (2006).","journal-title":"Clin. Pharmacokinet."},{"key":"1193_CR26","doi-asserted-by":"publisher","first-page":"6976","DOI":"10.1093\/nar\/gkq576","volume":"38","author":"MW Weng","year":"2010","unstructured":"Weng, M. W. et al. Repair of mitomycin C mono- and interstrand cross-linked DNA adducts by UvrABC: a new model. Nucleic Acids Res. 38, 6976\u20136984 https:\/\/doi.org\/10.1093\/nar\/gkq576 (2010).","journal-title":"Nucleic Acids Res."},{"key":"1193_CR27","unstructured":"JELMYTO (Mitomycin) for Pyelocalyceal Solution https:\/\/www.urogen.com\/download\/pdf\/jelmyto_prescribing.pdf (UroGen Pharma, 2024)."},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"e0175494","DOI":"10.1371\/journal.pone.0175494","volume":"12","author":"S Hori","year":"2017","unstructured":"Hori, S. et al. Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl)\u00a0nitrosamine induced bladder cancer mouse model. PLoS ONE 12, e0175494 https:\/\/doi.org\/10.1371\/journal.pone.0175494 (2017).","journal-title":"PLoS ONE"},{"key":"1193_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.27990","volume":"133","author":"I Shevchenko","year":"2013","unstructured":"Shevchenko, I. et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int. J. Cancer 133, 98\u2013107 https:\/\/doi.org\/10.1002\/ijc.27990 (2013).","journal-title":"Int. J. Cancer"},{"key":"1193_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cellimm.2015.02.003","volume":"294","author":"Y Zheng","year":"2015","unstructured":"Zheng, Y. et al. Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol. 294, 54\u201359 https:\/\/doi.org\/10.1016\/j.cellimm.2015.02.003 (2015).","journal-title":"Cell Immunol."},{"key":"1193_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/286170","volume":"2014","author":"JY Li","year":"2014","unstructured":"Li, J. Y. et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J. Immunol. Res. 2014, 286170 https:\/\/doi.org\/10.1155\/2014\/286170 (2014).","journal-title":"J. Immunol. Res."},{"key":"1193_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115057","volume":"162","author":"W Xiong","year":"2025","unstructured":"Xiong, W. et al. Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. Int. Immunopharmacol. 162, 115057 https:\/\/doi.org\/10.1016\/j.intimp.2025.115057 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"1193_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/blc-150039","volume":"2","author":"RL Steinberg","year":"2016","unstructured":"Steinberg, R. L., Thomas, L. J., Mott, S. L. & O\u2019Donnell, M. A. Bacillus Calmette\u2013Gu\u00e9rin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease. Bladder Cancer 2, 215\u2013224 https:\/\/doi.org\/10.3233\/blc-150039 (2016).","journal-title":"Bladder Cancer"},{"key":"1193_CR34","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/cncr.24914","volume":"116","author":"G Di Lorenzo","year":"2010","unstructured":"Di Lorenzo, G. et al. Gemcitabine versus Bacille Calmette\u2013Gu\u00e9rin after initial Bacille Calmette\u2013Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 116, 1893\u20131900 https:\/\/doi.org\/10.1002\/cncr.24914 (2010).","journal-title":"Cancer"},{"key":"1193_CR35","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","volume":"190","author":"EC Skinner","year":"2013","unstructured":"Skinner, E. C. et al. SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical Bacillus Calmette\u2013Gu\u00e9rin. J. Urol. 190, 1200\u20131204 https:\/\/doi.org\/10.1016\/j.juro.2013.04.031 (2013).","journal-title":"J. Urol."},{"key":"1193_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","volume":"189","author":"LJ Barlow","year":"2013","unstructured":"Barlow, L. J., McKiernan, J. M. & Benson, M. C. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous Bacillus Calmette\u2013Gu\u00e9rin therapy. J. Urol. 189, 834\u2013839 https:\/\/doi.org\/10.1016\/j.juro.2012.10.068 (2013).","journal-title":"J. Urol."},{"key":"1193_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/jco.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo, R. et al. Randomized phase III trial on gemcitabine versus\u00a0mitomycin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J. Clin. Oncol. 28, 543\u2013548 https:\/\/doi.org\/10.1200\/jco.2008.20.8199 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR38","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","volume":"15","author":"WS Tan","year":"2018","unstructured":"Tan, W. S. & Kelly, J. D. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat. Rev. Urol. 15, 667\u2013685 https:\/\/doi.org\/10.1038\/s41585-018-0092-z (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1193_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.urolonc.2024.12.264","volume":"43","author":"S Daneshmand","year":"2025","unstructured":"Daneshmand, S. et al. Development of TAR-200: a novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer. Urol. Oncol. 43, 286\u2013296 https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.264 (2025).","journal-title":"Urol. Oncol."},{"key":"1193_CR40","doi-asserted-by":"publisher","unstructured":"Daneshmand, S. et al. TAR-200 for Bacillus Calmette\u2013Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from the phase IIb SunRISe-1 study. J. Clin. Oncol. 43, 3578\u20133588 https:\/\/doi.org\/10.1200\/jco-25-01651 (2025).","DOI":"10.1200\/jco-25-01651"},{"key":"1193_CR41","first-page":"e17","volume":"213","author":"S Porten","year":"2025","unstructured":"Porten, S. et al. SunRISe-5: a phase 3, randomized, open-label study of TAR-200 compared with intravesical chemotherapy after Bacillus Calmette\u2013Gu\u00e9rin in recurrent high-risk non-muscle-invasive bladder cancer. J. Urol. 213, e17\u2013e18 (2025).","journal-title":"J. Urol."},{"key":"1193_CR42","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","volume":"31","author":"CP Dinney","year":"2013","unstructured":"Dinney, C. P., Greenberg, R. E. & Steinberg, G. D. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette\u2013Gu\u00e9rin. Urol. Oncol. 31, 1635\u20131642 https:\/\/doi.org\/10.1016\/j.urolonc.2012.04.010 (2013).","journal-title":"Urol. Oncol."},{"key":"1193_CR43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/5.suppl_4.S3","volume":"5","author":"SB Horwitz","year":"1994","unstructured":"Horwitz, S. B. Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 5, S3\u2013S6 (1994).","journal-title":"Ann. Oncol."},{"key":"1193_CR44","doi-asserted-by":"publisher","first-page":"11.9","DOI":"10.1016\/j.urolonc.2021.07.007","volume":"40","author":"R Hurle","year":"2022","unstructured":"Hurle, R. et al. Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: results of a prospective European multicentre study at 15 months from treatment start. Urol. Oncol. 40, 11.9\u201311.e15 https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.007 (2022).","journal-title":"Urol. Oncol."},{"key":"1193_CR45","unstructured":"US National Library of Medicine.ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05024773 (2026)."},{"key":"1193_CR46","doi-asserted-by":"publisher","first-page":"TPS885","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS885","volume":"43","author":"M Kates","year":"2025","unstructured":"Kates, M. et al. A phase III single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive carcinoma in situ of the bladder with or without Ta-T1 papillary disease (Orion-BC study). J. Clin. Oncol. 43, TPS885 https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.TPS885 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","volume":"18","author":"L Huang","year":"2025","unstructured":"Huang, L. et al. Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025). J. Hematol. Oncol. 18, 107 https:\/\/doi.org\/10.1186\/s13045-025-01734-x (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1193_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/BLC-230039","volume":"9","author":"V Kumar","year":"2023","unstructured":"Kumar, V. & Wei, X. X. Immune checkpoint inhibitors in metastatic bladder and other solid malignancies: how long is enough? Bladder Cancer 9, 101\u2013110 https:\/\/doi.org\/10.3233\/BLC-230039 (2023).","journal-title":"Bladder Cancer"},{"key":"1193_CR49","doi-asserted-by":"publisher","first-page":"34066","DOI":"10.18632\/oncotarget.26122","volume":"9","author":"A Hashizume","year":"2018","unstructured":"Hashizume, A. et al. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette\u2013Guerin. Oncotarget 9, 34066\u201334078 https:\/\/doi.org\/10.18632\/oncotarget.26122 (2018).","journal-title":"Oncotarget"},{"key":"1193_CR50","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 https:\/\/doi.org\/10.1038\/nrc3239 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1193_CR51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H., Orhan, A., Christensen, J. P. & G\u00f6genur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 https:\/\/doi.org\/10.1038\/s41416-020-01048-4 (2021).","journal-title":"Br. J. Cancer"},{"key":"1193_CR52","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/s1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919\u2013930 https:\/\/doi.org\/10.1016\/s1470-2045(21)00147-9 (2021).","journal-title":"Lancet Oncol."},{"key":"1193_CR53","unstructured":"Kulkarni, G. S. et al. Pembrolizumab in participants with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer: 5-year follow-up from cohort A of the phase 2 KEYNOTE-057 trial. Presented at Society of Urologic Oncology 23rd Annual Meeting https:\/\/suo-abstracts.secure-platform.com\/a\/gallery\/rounds\/15\/details\/2400 (2022)."},{"key":"1193_CR54","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1200\/jco.2026.44.7_suppl.743","volume":"44","author":"R Satkunasivam","year":"2026","unstructured":"Satkunasivam, R. et al. ADVANCED-2: interim efficacy and safety data in BCG-unresponsive participants with high-grade non-muscle invasive bladder cancer. J. Clin. Oncol. 44, 743 https:\/\/doi.org\/10.1200\/jco.2026.44.7_suppl.743 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.euf.2018.08.005","volume":"4","author":"R Railkar","year":"2018","unstructured":"Railkar, R. & Agarwal, P. K. Photodynamic therapy in the treatment of bladder cancer: past challenges and current innovations. Eur. Urol. Focus. 4, 509\u2013511 https:\/\/doi.org\/10.1016\/j.euf.2018.08.005 (2018).","journal-title":"Eur. Urol. Focus."},{"key":"1193_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.euros.2022.04.015","volume":"41","author":"GS Kulkarni","year":"2022","unstructured":"Kulkarni, G. S. et al. A Phase 1b clinical study of intravesical photodynamic therapy in patients with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer. Eur. Urol. Open Sci. 41, 105\u2013111 https:\/\/doi.org\/10.1016\/j.euros.2022.04.015 (2022).","journal-title":"Eur. Urol. Open Sci."},{"key":"1193_CR57","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","volume":"106","author":"S Kwiatkowski","year":"2018","unstructured":"Kwiatkowski, S. et al. Photodynamic therapy \u2014 mechanisms, photosensitizers and combinations. Biomed. Pharmacother. 106, 1098\u20131107 https:\/\/doi.org\/10.1016\/j.biopha.2018.07.049 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"1193_CR58","unstructured":"Theralase Technologies Inc. Anti-Cancer Therapy (ACT): Photo Dynamic Therapy \u2014 Photo Dynamic Compounds (Theralase Technologies, 2020)."},{"key":"1193_CR59","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03945162 (2025)."},{"key":"1193_CR60","doi-asserted-by":"publisher","first-page":"PD12","DOI":"10.1097\/01.JU.0001191388.74345.c9.17","volume":"213","author":"G Kulkarni","year":"2025","unstructured":"Kulkarni, G. et al. Interim analysis of light-activated TLD-1433 in a phase II clinical study of BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ. J. Urol. 213, PD12\u2013PD13 https:\/\/doi.org\/10.1097\/01.JU.0001191388.74345.c9.17 (2025).","journal-title":"J. Urol."},{"key":"1193_CR61","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737140.2023.2203385","volume":"23","author":"C Tholomier","year":"2023","unstructured":"Tholomier, C. et al. The current status of gene therapy in bladder cancer. Expert Rev. Anticancer. Ther. 23, 531\u2013543 https:\/\/doi.org\/10.1080\/14737140.2023.2203385 (2023).","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"1193_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1359725","volume":"14","author":"VM Narayan","year":"2024","unstructured":"Narayan, V. M. et al. Mechanism of action of nadofaragene firadenovec-vncg. Front. Oncol. 14, 1359725 https:\/\/doi.org\/10.3389\/fonc.2024.1359725 (2024).","journal-title":"Front. Oncol."},{"key":"1193_CR63","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00345-018-2553-7","volume":"37","author":"JJ Duplisea","year":"2019","unstructured":"Duplisea, J. J. et al. The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J. Urol. 37, 2041\u20132049 https:\/\/doi.org\/10.1007\/s00345-018-2553-7 (2019).","journal-title":"World J. Urol."},{"key":"1193_CR64","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","volume":"190","author":"CP Dinney","year":"2013","unstructured":"Dinney, C. P. et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette\u2013Gu\u00e9rin failures in nonmuscle invasive bladder cancer. J. Urol. 190, 850\u2013856 https:\/\/doi.org\/10.1016\/j.juro.2013.03.030 (2013).","journal-title":"J. Urol."},{"key":"1193_CR65","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/s1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian, S. A. et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 22, 107\u2013117 https:\/\/doi.org\/10.1016\/s1470-2045(20)30540-4 (2021).","journal-title":"Lancet Oncol."},{"key":"1193_CR66","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ju.0000000000004020","volume":"212","author":"VM Narayan","year":"2024","unstructured":"Narayan, V. M. et al. Efficacy of intravesical nadofaragene firadenovec for patients with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. J. Urol. 212, 74\u201386 https:\/\/doi.org\/10.1097\/ju.0000000000004020 (2024).","journal-title":"J. Urol."},{"key":"1193_CR67","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1158\/1078-0432.Ccr-05-1059","volume":"12","author":"N Ramesh","year":"2006","unstructured":"Ramesh, N. et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin. Cancer Res. 12, 305\u2013313 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-1059 (2006).","journal-title":"Clin. Cancer Res."},{"key":"1193_CR68","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14712598.2024.2445674","volume":"25","author":"AR Steinmetz","year":"2025","unstructured":"Steinmetz, A. R. et al. Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin. Biol. Ther. 25, 149\u2013159 https:\/\/doi.org\/10.1080\/14712598.2024.2445674 (2025).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1193_CR69","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/blood.V77.6.1131.1131","volume":"77","author":"JC Gasson","year":"1991","unstructured":"Gasson, J. C. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 77, 1131\u20131145 (1991).","journal-title":"Blood"},{"key":"1193_CR70","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi, Y. et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res. 16, 126\u2013133 https:\/\/doi.org\/10.1038\/sj.cr.7310017 (2006).","journal-title":"Cell Res."},{"key":"1193_CR71","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s1470-2045(26)00194-4","volume":"27","author":"MD Tyson","year":"2026","unstructured":"Tyson, M. D. et al. Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive non\u2013muscle invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm phase 3 trial. Lancet Oncol. 27, 983\u2013993 https:\/\/doi.org\/10.1016\/s1470-2045(26)00194-4 (2026).","journal-title":"Lancet Oncol."},{"key":"1193_CR72","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04752722 (2026)."},{"key":"1193_CR73","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1097\/01.JU.0001192572.07890.f8.04","volume":"215","author":"AM Kamat","year":"2026","unstructured":"Kamat, A. M. et al. A non-viral intravesical gene therapy for BCG-unresponsive NMIBC with CIS, with or without papillary disease: pivotal phase 2 interim results of detalimogene voraplasmid. J. Urol. 215, e2\u2013e3 (2026).","journal-title":"J. Urol."},{"key":"1193_CR74","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/bju.16509","volume":"135","author":"JI Taylor","year":"2025","unstructured":"Taylor, J. I. et al. Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 135, 260\u2013268 https:\/\/doi.org\/10.1111\/bju.16509 (2025).","journal-title":"BJU Int."},{"key":"1193_CR75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/blc-150008","volume":"1","author":"RL Steinberg","year":"2015","unstructured":"Steinberg, R. L., Thomas, L. J., O\u2019Donnell, M. A. & Nepple, K. G. Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer. Bladder Cancer 1, 65\u201372 https:\/\/doi.org\/10.3233\/blc-150008 (2015).","journal-title":"Bladder Cancer"},{"key":"1193_CR76","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/ju.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg, R. L. et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J. Urol. 203, 902\u2013909 https:\/\/doi.org\/10.1097\/ju.0000000000000688 (2020).","journal-title":"J. Urol."},{"key":"1193_CR77","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2024.12.005","volume":"8","author":"J Taylor","year":"2024","unstructured":"Taylor, J. et al. Oncologic outcomes of sequential intravesical gemcitabine and docetaxel compared with Bacillus Calmette\u2013Gu\u00e9rin in patients with Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle invasive bladder cancer. Eur. Urol. Oncol. 8, 469\u2013476 https:\/\/doi.org\/10.1016\/j.euo.2024.12.005 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1193_CR78","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06663137 (2026)."},{"key":"1193_CR79","unstructured":"Lotan, Y. et al. Prospective open-label study to evaluate the safety and efficacy of intravesical sustained-release gemcitabine docetaxel combination (NDV-01) in high-risk NMIBC: update with 6-month complete response data. Presented at Society of Urologic Oncology Annual Meeting, abstract 143 https:\/\/suo-abstracts.secure-platform.com\/a\/gallery\/rounds\/24\/details\/4577 (2025)."},{"key":"1193_CR80","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/JU.0000000000005224","volume":"216","author":"GJ DeCastro","year":"2026","unstructured":"DeCastro, G. J. et al. A phase 2 trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of non-muscle-invasive BCG-unresponsive urothelial carcinoma of the bladder. J. Urol. 216, 676\u2013684 https:\/\/doi.org\/10.1097\/JU.0000000000005224 (2026).","journal-title":"J. Urol."},{"key":"1193_CR81","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","volume":"17","author":"JH van Puffelen","year":"2020","unstructured":"van Puffelen, J. H. et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat. Rev. Urol. 17, 513\u2013525 https:\/\/doi.org\/10.1038\/s41585-020-0346-4 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"1193_CR82","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul, S. & Lal, G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front. Immunol. 8, 1124 https:\/\/doi.org\/10.3389\/fimmu.2017.01124 (2017).","journal-title":"Front. Immunol."},{"key":"1193_CR83","doi-asserted-by":"publisher","first-page":"EVIDoa2200167","DOI":"10.1056\/EVIDoa2200167","volume":"2","author":"K Chamie","year":"2023","unstructured":"Chamie, K. et al. IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer. NEJM Evid. 2, EVIDoa2200167 https:\/\/doi.org\/10.1056\/EVIDoa2200167 (2023).","journal-title":"NEJM Evid."},{"key":"1193_CR84","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1158\/1078-0432.Ccr-25-1231","volume":"31","author":"BL Heiss","year":"2025","unstructured":"Heiss, B. L. et al. FDA approval summary: nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ. Clin. Cancer Res. 31, 4223\u20134229 https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-1231 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1193_CR85","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-024-03025-3","volume":"30","author":"R Li","year":"2024","unstructured":"Li, R. et al. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat. Med. 30, 2216\u20132223 https:\/\/doi.org\/10.1038\/s41591-024-03025-3 (2024).","journal-title":"Nat. Med."},{"key":"1193_CR86","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.urolonc.2022.05.013","volume":"41","author":"C Chu","year":"2023","unstructured":"Chu, C. & Pietzak, E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non\u2212muscle invasive bladder cancer. Invited review for special issue \u2018Seminar: treatment advances and molecular biology insights in urothelial carcinoma\u2019. Urol. Oncol. Semin. Orig. Invest. 41, 398\u2013409 https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.013 (2023).","journal-title":"Urol. Oncol. Semin. Orig. Invest."},{"key":"1193_CR87","doi-asserted-by":"publisher","first-page":"PR005","DOI":"10.1158\/1557-3265.BLADDER24-PR005","volume":"30","author":"SM Alam","year":"2024","unstructured":"Alam, S. M. et al. Abstract PR005: Final results from a phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette\u2013Gu\u00e9rin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer. Clin. Cancer Res. 30, PR005 https:\/\/doi.org\/10.1158\/1557-3265.BLADDER24-PR005 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1193_CR88","doi-asserted-by":"publisher","first-page":"TPS909","DOI":"10.1200\/JCO.2026.44.7_suppl.TPS909","volume":"44","author":"EJ Pietzak","year":"2026","unstructured":"Pietzak, E. J. et al. The GAIN trial: gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent \u2018BCG-exposed\u2019 high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303). J. Clin. Oncol. 44, TPS909 https:\/\/doi.org\/10.1200\/JCO.2026.44.7_suppl.TPS909 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR89","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04164082 (2026)."},{"key":"1193_CR90","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2025.43.5_suppl.667","volume":"43","author":"NM Hahn","year":"2025","unstructured":"Hahn, N. M. et al. A phase 1\/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4). J. Clin. Oncol. 43, 667 https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.667 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR91","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40364-024-00628-3","volume":"12","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Abscopal effect: from a rare phenomenon to a new frontier in cancer therapy. Biomarker Res. 12, 98 https:\/\/doi.org\/10.1186\/s40364-024-00628-3 (2024).","journal-title":"Biomarker Res."},{"key":"1193_CR92","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1200\/jco.2026.44.16_suppl.4599","volume":"44","author":"Z Li","year":"2026","unstructured":"Li, Z. et al. Final results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for high-risk non\u2013muscle-invasive bladder cancer patients unresponsive to Bacillus Calmette\u2013Gu\u00e9rin. J. Clin. Oncol. 44, 4599 https:\/\/doi.org\/10.1200\/jco.2026.44.16_suppl.4599 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR93","unstructured":"TEVIMBRA (Tislelizumab-jsgr) Injection, for Intravenous Use https:\/\/www.beigene.com\/PDF\/TEVIMBRAUSPI.pdf (BeiGene USA, 2024)."},{"key":"1193_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1543837","volume":"15","author":"J Kattan","year":"2025","unstructured":"Kattan, J. et al. The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder cancer. Front. Oncol. 15, 1543837 https:\/\/doi.org\/10.3389\/fonc.2025.1543837 (2025).","journal-title":"Front. Oncol."},{"key":"1193_CR95","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/jco.23.02510","volume":"42","author":"DM Dahl","year":"2024","unstructured":"Dahl, D. M. et al. Bladder-preserving trimodality treatment for high-grade T1 bladder cancer: results from phase\u00a0II protocol NRG oncology\/RTOG 0926. J. Clin. Oncol. 42, 4095\u20134102 https:\/\/doi.org\/10.1200\/jco.23.02510 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001110440.53375.7d(2025)","volume":"213","author":"T Bivalacqua","year":"2025","unstructured":"Bivalacqua, T. et al. Updates to the Core-008 trial protocol: a phase 2 multiarm, multi-cohort study to evaluate intravesical cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer. J. Urol. 213, e15 https:\/\/doi.org\/10.1097\/01.JU.0001110440.53375.7d(2025) (2025).","journal-title":"J. Urol."},{"key":"1193_CR97","doi-asserted-by":"publisher","DOI":"10.1097\/01.JU.0001008756.24343.22.06","volume":"211","author":"A Steinmetz","year":"2024","unstructured":"Steinmetz, A. et al. Novel combination therapy using interferon gene therapy and gemcitabine in murine bladder cancer cell lines. J. Urol. 211, e1079 https:\/\/doi.org\/10.1097\/01.JU.0001008756.24343.22.06 (2024).","journal-title":"J. Urol."},{"key":"1193_CR98","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189\u20131201 https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031 (2017).","journal-title":"Cell Rep."},{"key":"1193_CR99","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","volume":"186","author":"S Terawaki","year":"2011","unstructured":"Terawaki, S. et al. IFN-\u03b1 directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186, 2772\u20132779 https:\/\/doi.org\/10.4049\/jimmunol.1003208 (2011).","journal-title":"J. Immunol."},{"key":"1193_CR100","doi-asserted-by":"publisher","first-page":"e1577125","DOI":"10.1080\/2162402x.2019.1577125","volume":"8","author":"D Plote","year":"2019","unstructured":"Plote, D. et al. Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology 8, e1577125 https:\/\/doi.org\/10.1080\/2162402x.2019.1577125 (2019).","journal-title":"Oncoimmunology"},{"key":"1193_CR101","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002633.05","volume":"207","author":"AP Mitra","year":"2022","unstructured":"Mitra, A. P. et al. MP54-05 evaluating intravesical nadofaragene firadenovec and immune checkpoint blockade combination therapy in BCG-unresponsive non\u2013muscle-invasive bladder cancer: evidence from a phase 3 trial. J. Urol. 207, e927 https:\/\/doi.org\/10.1097\/JU.0000000000002633.05 (2022).","journal-title":"J. Urol."},{"key":"1193_CR102","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06545955 (2026)."},{"key":"1193_CR103","unstructured":"US National LIbrary of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02773849 (2024)."},{"key":"1193_CR104","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02625961 (2026)."},{"key":"1193_CR105","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/s1470-2045(24)00178-5","volume":"25","author":"A Necchi","year":"2024","unstructured":"Necchi, A. et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 25, 720\u2013730 https:\/\/doi.org\/10.1016\/s1470-2045(24)00178-5 (2024).","journal-title":"Lancet Oncol."},{"key":"1193_CR106","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06211764 (2026)."},{"key":"1193_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04452591 (2026)."},{"key":"1193_CR108","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05951179 (2026)."},{"key":"1193_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03022825 (2025)."},{"key":"1193_CR110","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.1097\/01.JU.0001109848.08748.9e.12","volume":"213","author":"SS Chang","year":"2025","unstructured":"Chang, S. S. et al. An update on QUILT-3.032: complete responses to N-803 plus BCG therapy in BCG-unresponsive bladder carcinoma in situ (CIS) with or without Ta\/T1 papillary disease. J. Urol. 213, e392\u2013e393 (2025).","journal-title":"J. Urol."},{"key":"1193_CR111","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04387461 (2024)."},{"key":"1193_CR112","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06567743 (2026)."},{"key":"1193_CR113","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT00981656 (2024)."},{"key":"1193_CR114","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04640623 (2026)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01193-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01193-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:22:02Z","timestamp":1792106522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01193-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":114,"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01193-0","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"21 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.D. has served as a consultant and received funding from Photocure, Pacific Edge, Ferring, BMS, Johnson & Johnson, Protara, Urogen, Pfizer, CG Oncology, Immunity Bio, enGene and AstraZeneca. S.A.B. has served as a consultant and received funding from Ferring Pharmaceuticals Inc., FerGene, ArTara, Johnson & Johnson, and Prokarium. J.J.M. has served as a consultant for Merck, AstraZeneca, Janssen, BMS, UroGen, Prokarium, Pfizer, Seagen\/Astellas, Protara and Immunity Bio; has received research funding from the Veterans Health Administration, the NIH and the US Department of Defense; and has received compensation for talks\/educational courses from the American Urological Association, OncLive, Olympus and UroToday. Y.L. has served as a consultant\/adviser and received funding from Relmada, Trigone Pharma, Pacific Edge, Photocure, AstraZeneca, Vessi Medical, Nucleix, Merck, enGene, CAPS Medical, Ferring, Ambu, Seattle Genetics, Verity Pharmaceuticals, Urogen, Stimit, Convergent Genomics, Aura Biosciences, Nonagen, Valar Lab, Pfizer, Phinomics, CG Oncology, Virtuoso Surgical, Uroviu, On Target Lab, Promis Diagnostics and Uroessentials; Y.L. received funds for involvement with a data monitoring and safety committee from Urogen; and Y.L. discloses nonfinancial scientific study or trial involvement with Johnson & Johnson, Merck, enGene, Pfizer, FKD, MDxHealth and GenomeDx Biosciences, Inc. W.K. has served as a consultant or had advisory roles for Ferring, AstraZeneca, BMS, Merck, Janssen, Bayer, Astellas, Seagen, Pfizer, EMD Serono, enGene, Photocure and CG Oncology. G.S.K. has received honoraria from or served on advisory boards for Merck, EMD Serono, Pfizer, BMS, Theralase, Johnson & Johnson, AAA\/Novartis, Ferring, Astellas, Verity, Knight Therapeutics, enGene, CG Oncology, Protara and AbbVie; served as consultant for Verity, TerSera, AstraZeneca, Photocure, Johnson & Johnson, and Ferring; and participated in clinical trials for Merck, Seagen, Pfizer, Theralase, BMS, Johnson & Johnson, Verity, CG Oncology, Ferring and enGene. P.G. has participated as advisory board\/speaker or received research funding from Medac, Ferring, Janssen, MSD, Merck, Photocure, Nucleix and AstraZeneca. P.A. is a member of the data monitoring board of ABLE-22. J.S.J. is an employee of Ferring Pharmaceuticals A\/S. K.J. is an employee of Ferring Pharmaceuticals A\/S.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}